Randomized trial · people
Teriparatide: fewer new vertebral fractures than risedronate in VERO
Checked against the paper Randomized trialPublished by PepVault
The takeaway
In this head-to-head trial, teriparatide led to fewer new spine and clinical fractures than risedronate over 24 months in severe post-menopausal osteoporosis, while the difference in non-vertebral fractures was not significant.
- Kind
- Randomized trial
- Studied in
- People
- Published
- 2018
- Journal
- Lancet
What they tested
The team tested whether teriparatide prevents new fractures better than risedronate in women with severe osteoporosis after menopause.
How the study was done
A double-blind, double-dummy randomized controlled trial at many centers. Each group had 680 post-menopausal women who already had vertebral (spine) fractures and low bone density. One group got daily teriparatide 20 μg shots plus a weekly dummy pill. The other got weekly risedronate 35 mg pills plus daily dummy shots, for 24 months.

What they found
After 24 months, a new spine fracture showed up on X-ray in 28 (5.4%) of 680 women on teriparatide and in 64 (12.0%) of 680 on risedronate, a risk ratio of 0.44. Clinical fractures, meaning non-vertebral fractures plus spine fractures that caused symptoms, were also less common with teriparatide: 30 (4.8%) vs 61 (9.8%), a hazard ratio of 0.48. Non-vertebral fragility fractures happened in 25 (4.0%) women on teriparatide and 38 (6.1%) on risedronate, but this gap was not statistically significant (p=0.10).
What it doesn’t show
Only post-menopausal women with severe osteoporosis and existing spine fractures took part, so the results may not apply to milder cases or to men. The study was funded by Lilly.
The paper
Kendler et al. Effects of teriparatide and risedronate on new fractures in post-menopausal women with severe osteoporosis (VERO): a multicentre, double-blind, double-dummy, randomised controlled trial. Lancet. 2018.
The compound
More studies on Teriparatide
- Abaloparatide, teriparatide beat other drugs on spine BMD in menMeta-analysis · people · 2025
- Teriparatide cut fracture risk vs bisphosphonates (RR 0.61)Meta-analysis · people · 2024
- Abaloparatide: larger hip BMD gains than teriparatide at 24 weeksMeta-analysis · people · 2023
- Teriparatide: more bony union at 6 months than zoledronate after PLIFRandomized trial · people · 2022
- Teriparatide: 45.4% of jaw osteonecrosis lesions resolved by 52 weeksRandomized trial · people · 2020
- Teriparatide then denosumab: spine density up 18.3% over 4 yearsRandomized trial · people · 2015
- Every study on Teriparatide
Researched and drafted with AI, then checked claim by claim against the primary sources linked below by a separate review pass. Published by PepVault. Last reviewed . Spot an error? feedback@pepvault.app. How we research. This page reports one study; it is not medical advice.